Insmed (NASDAQ:INSM) CEO William Lewis Sells 7,605 Shares

by · The Cerbat Gem

Insmed, Inc. (NASDAQ:INSM – Get Free Report) CEO William Lewis sold 7,605 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total value of $777,763.35. Following the completion of the sale, the chief executive officer owned 265,432 shares of the company’s stock, valued at $27,145,730.64. This represents a 2.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

William Lewis also recently made the following trade(s):

  • On Thursday, April 16th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $143.97, for a total value of $1,540,335.03.
  • On Monday, April 6th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $163.22, for a total value of $1,746,290.78.
  • On Thursday, March 19th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $143.52, for a total value of $1,535,520.48.

Insmed Trading Down 10.2%

NASDAQ INSM traded down $10.70 on Friday, reaching $94.22. The company had a trading volume of 7,955,715 shares, compared to its average volume of 2,804,548. The stock’s 50 day moving average is $131.53 and its 200-day moving average is $155.38. The stock has a market cap of $20.42 billion, a price-to-earnings ratio of -16.39 and a beta of 0.79. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80. Insmed, Inc. has a 52 week low of $70.57 and a 52 week high of $212.75.

Insmed (NASDAQ:INSM – Get Free Report) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The firm had revenue of $305.96 million during the quarter, compared to analysts’ expectations of $300.81 million. During the same period in the previous year, the firm earned ($1.42) earnings per share. The company’s revenue was up 229.7% on a year-over-year basis. Equities analysts predict that Insmed, Inc. will post -2.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on INSM. Royal Bank Of Canada decreased their target price on Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a research note on Friday. Morgan Stanley raised Insmed from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $166.00 to $212.00 in a research note on Monday, March 30th. Raymond James Financial began coverage on Insmed in a research note on Friday, April 10th. They issued an “outperform” rating and a $200.00 target price for the company. Roth Mkm reissued a “buy” rating and issued a $212.00 target price on shares of Insmed in a research note on Friday, April 17th. Finally, Leerink Partners boosted their target price on Insmed from $210.00 to $215.00 and gave the company an “outperform” rating in a research note on Tuesday, March 24th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Insmed has an average rating of “Moderate Buy” and a consensus target price of $210.50.

Get Our Latest Analysis on Insmed

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. CIBC Private Wealth Group LLC boosted its position in Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares during the last quarter. CoreCap Advisors LLC acquired a new position in Insmed during the fourth quarter valued at approximately $27,000. SBI Securities Co. Ltd. boosted its position in Insmed by 404.9% during the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 166 shares during the last quarter. GraniteShares Advisors LLC acquired a new position in Insmed during the fourth quarter valued at approximately $30,000. Finally, Reflection Asset Management acquired a new position in Insmed during the fourth quarter valued at approximately $30,000.

About Insmed

(Get Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

Further Reading